Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ardelyx Inc (ARDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 275,674
  • Shares Outstanding, K 47,530
  • Annual Sales, $ 0 K
  • Annual Income, $ -112,390 K
  • 36-Month Beta 0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.25

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.15 +17.48%
on 11/15/17
6.80 -11.03%
on 12/01/17
+0.40 (+7.08%)
since 11/13/17
3-Month
4.75 +27.37%
on 10/27/17
8.65 -30.06%
on 10/12/17
+0.60 (+11.01%)
since 09/13/17
52-Week
4.05 +49.38%
on 06/07/17
15.40 -60.71%
on 03/20/17
-8.90 (-59.53%)
since 12/13/16

Most Recent Stories

More News
Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited (Fosun Pharma) providing Fosun...

ARDX : 6.05 (+4.31%)
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime

AKTX : 4.26 (+0.47%)
BTX : 2.33 (+1.75%)
JYNT : 5.17 (unch)
ARDX : 6.05 (+4.31%)
TLRD : 20.46 (+5.14%)
5 Affordable Breakout Stocks Offering Excellent Returns

If properly implemented, such a strategy has the ability to deliver impressive returns.

AKTX : 4.26 (+0.47%)
BTX : 2.33 (+1.75%)
JYNT : 5.17 (unch)
ARDX : 6.05 (+4.31%)
TLRD : 20.46 (+5.14%)
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan

Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced that they have entered into a license agreement that provides Kyowa Hakko Kirin with exclusive...

ARDX : 6.05 (+4.31%)
Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline

Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin...

ARDX : 6.05 (+4.31%)
Stock Performance Review on Biotech Industry -- Ardelyx, Bellicum Pharma, Iovance Biotherapeutics, and Inotek Pharma

If you want a Stock Review on ARDX, BLCM, IOVA, or ITEK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, the NASDAQ Composite ended the...

IOVA : 8.70 (-2.25%)
ITEK : 2.31 (-5.33%)
ARDX : 6.05 (+4.31%)
BLCM : 8.87 (+4.23%)
Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress

Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September 30, 2017.

ARDX : 6.05 (+4.31%)
Aurora Diagnostics Announces the Acquisition of the CytoPath Pathology Practice in Alabama

Aurora Diagnostics, a leading independent pathology services and cancer diagnostics company, today announced the acquisition of CytoPath, bringing to 30 the number of affiliated local pathology...

ARDX : 6.05 (+4.31%)
Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling

Ardelyx, Inc. (NASDAQ: ARDX) today reported that data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation (IBS-C) through...

ARDX : 6.05 (+4.31%)
Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

IRWD : 15.55 (-0.38%)
AGN : 169.24 (-1.53%)
ARDX : 6.05 (+4.31%)
SGYP : 2.01 (+5.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

2nd Resistance Point 6.45
1st Resistance Point 6.25
Last Price 6.05
1st Support Level 5.80
2nd Support Level 5.56

See More

52-Week High 15.40
Fibonacci 61.8% 11.06
Fibonacci 50% 9.73
Fibonacci 38.2% 8.39
Last Price 6.05
52-Week Low 4.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.